Elevated Anti-Müllerian Hormone Is an Independent Risk Factor for Preterm Birth Among Patients With Overweight Polycystic Ovary Syndrome

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2021 Dec 27

PMID 34956097

Citations 7

Authors

Mingze Du

Junwei Zhang

Xiaona Yu

Yichun Guan

Affiliations

Soon will be listed here.

Abstract

Objective: To explore whether elevated anti-Müllerian hormone (AMH) levels affect the rate of preterm birth (PTB) among PCOS patients with different BMIs.

Methods: In this retrospective cohort study, patients with PCOS who had undergone IVF/ICSI from January 2017 to December 2019 were included for potential evaluation. A total of 2368 singleton live births from PCOS patients were included. According to the BMI, all the PCOS patients were divided into two groups: BMI<24 kg/m and BMI≥24 kg/m. In total, 1339 PCOS patients with a BMI<24 kg/m were grouped according to their serum AMH levels: ① <2.71 ng/ml (n=333), ② 2.71-4.08 ng/ml (n=330), ③ 4.09-6.45 ng/ml (n=351), and ④ >6.45 ng/ml (n=325). Additionally, 1029 cycles of patients with a BMI≥24 kg/m were grouped according to the serum AMH level: ① <2.71 ng/ml (n=255), ② 2.71-4.08 ng/ml (n=267), ③ 4.09-6.45 ng/ml (n=239), and ④ >6.45 ng/ml (n=268), with <2.71 ng/ml being considered the reference group. The grouping was based mainly on the interquartile range of serum AMH levels. The primary outcome of the study was PTB. The secondary outcomes were low birth weight (LBW), small for gestational age (SGA), macrosomia and large for gestational age (LGA).

Results: Regarding PCOS patients with a BMI<24 kg/m, compared with the PTB rate of the AMH <2.71 ng/ml group, the PTB rates of the different groups were not significantly different (AMH 2.71-4.08, AOR (95% CI)=1.01 (0.52-2.00), P=0.99; AMH 4.09-6.45, AOR (95% CI)=0.93 (0.45-1.91), P=0.85; AMH>6.45, AOR (95% CI)=0.78 (0.35-1.73), P=0.54). Regarding PCOS patients with a BMI ≥24 kg/m, compared with the PTB rate of the AMH <2.71 ng/ml group, the PTB rate of the AMH>6.45 ng/ml group was significantly higher (OR=2.47; 95% CI=1.34-4.55). After multiple logistic regression analysis, the risk of PTB in the AMH>6.45 ng/ml group was 2.1 times that in the AMH<2.71 ng/ml group (AOR=2.1, 95% CI=1.01-4.37, P=0.04). However, no statistically significant difference was found in the rate of SGA, LBW, macrosomia or LGA among patients in the different serum AMH groups.

Conclusion: For PCOS patients, a BMI≥24 kg/m plus serum AMH>6.45 ng/ml (75th percentile) is an independent risk factor for PTB.

Citing Articles

Hydroxychloroquine enhances insulin sensitivity and ameliorates abnormal lipid metabolism in obese women with polycystic ovary syndrome.

Wang R, Qi S, Wang Q, Lang J, Pang C, Wang K BMC Endocr Disord. 2025; 25(1):2.

PMID: 39748269 PMC: 11697925. DOI: 10.1186/s12902-024-01827-7.

Association between serum AMH levels and IVF/ICSI outcomes in patients with polycystic ovary syndrome: a systematic review and meta-analysis.

Yuwen T, Yang Z, Cai G, Feng G, Liu Q, Fu H Reprod Biol Endocrinol. 2023; 21(1):95.

PMID: 37872575 PMC: 10591359. DOI: 10.1186/s12958-023-01153-y.

Exploring the mechanism of clomiphene citrate to improve ovulation disorder in PCOS rats based on follicular fluid metabolomics.

He Y, Wang X, Liu Q, Liu H, Yang S Naunyn Schmiedebergs Arch Pharmacol. 2023; 397(4):2281-2296.

PMID: 37815607 DOI: 10.1007/s00210-023-02750-9.

Serum anti-Müllerian hormone levels are associated with perinatal outcomes in women undergoing IVF/ICSI: A multicenter retrospective cohort study.

He Y, Su K, Cai J, Meng Q, Wu Y, Huang H Front Endocrinol (Lausanne). 2023; 14:1081069.

PMID: 36896183 PMC: 9990865. DOI: 10.3389/fendo.2023.1081069.

Endocrine and metabolic interactions in healthy pregnancies and hyperinsulinemic pregnancies affected by polycystic ovary syndrome, diabetes and obesity.

Neven A, Mousa A, Boyle J, Teede H Front Endocrinol (Lausanne). 2023; 13:993619.

PMID: 36733795 PMC: 9886898. DOI: 10.3389/fendo.2022.993619.

References

Wachs D, Coffler M, Malcom P, Chang R . Serum anti-mullerian hormone concentrations are not altered by acute administration of follicle stimulating hormone in polycystic ovary syndrome and normal women. J Clin Endocrinol Metab. 2007; 92(5):1871-4. DOI: 10.1210/jc.2006-2425. View

Sha T, Wang X, Cheng W, Yan Y . A meta-analysis of pregnancy-related outcomes and complications in women with polycystic ovary syndrome undergoing IVF. Reprod Biomed Online. 2019; 39(2):281-293. DOI: 10.1016/j.rbmo.2019.03.203. View

La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio A . Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update. 2009; 16(2):113-30. DOI: 10.1093/humupd/dmp036. View

Wang T, Zhang J, Lu X, Xi W, Li Z . Maternal early pregnancy body mass index and risk of preterm birth. Arch Gynecol Obstet. 2010; 284(4):813-9. DOI: 10.1007/s00404-010-1740-6. View

Mulders A, Laven J, Eijkemans M, de Jong F, Themmen A, Fauser B . Changes in anti-Müllerian hormone serum concentrations over time suggest delayed ovarian ageing in normogonadotrophic anovulatory infertility. Hum Reprod. 2004; 19(9):2036-42. DOI: 10.1093/humrep/deh373. View

Arango N, Kobayashi A, Wang Y, Jamin S, Lee H, Orvis G . A mesenchymal perspective of Müllerian duct differentiation and regression in Amhr2-lacZ mice. Mol Reprod Dev. 2008; 75(7):1154-62. DOI: 10.1002/mrd.20858. View

Kim S, Kim Y, Lee M, Chung Y, Jeung I, Kim M . Müllerian inhibiting substance/anti-Müllerian hormone type II receptor protein and mRNA expression in the healthy and cancerous endometria. Oncol Lett. 2019; 17(1):532-538. PMC: 6313180. DOI: 10.3892/ol.2018.9565. View

Sirmans S, Pate K . Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol. 2014; 6:1-13. PMC: 3872139. DOI: 10.2147/CLEP.S37559. View

Li R, Zhang Q, Yang D, Li S, Lu S, Wu X . Prevalence of polycystic ovary syndrome in women in China: a large community-based study. Hum Reprod. 2013; 28(9):2562-9. DOI: 10.1093/humrep/det262. View

10.

Kim S, Moon H, Lee M, Chung Y, Song J, Cho H . The expression of Müllerian inhibiting substance/anti-Müllerian hormone type II receptor in myoma and adenomyosis. Obstet Gynecol Sci. 2018; 61(1):127-134. PMC: 5780307. DOI: 10.5468/ogs.2018.61.1.127. View

11.

Zhang J, Du M, Sun L . Supraphysiological estradiol levels on the hCG trigger day are associated with SGA for singletons born from fresh embryo transfer. J Dev Orig Health Dis. 2021; 13(2):244-251. DOI: 10.1017/S2040174421000234. View

12.

March W, Moore V, Willson K, Phillips D, Norman R, Davies M . The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 2009; 25(2):544-51. DOI: 10.1093/humrep/dep399. View

13.

Hart R, Doherty D, Norman R, Franks S, Dickinson J, Hickey M . Serum antimullerian hormone (AMH) levels are elevated in adolescent girls with polycystic ovaries and the polycystic ovarian syndrome (PCOS). Fertil Steril. 2010; 94(3):1118-21. DOI: 10.1016/j.fertnstert.2009.11.002. View

14.

Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz B . The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016; 31(12):2841-2855. DOI: 10.1093/humrep/dew218. View

15.

Huang X, Wang Q, Liu T, Pei T, Liu D, Zhu H . Body fat indices as effective predictors of insulin resistance in obese/non-obese polycystic ovary syndrome women in the Southwest of China. Endocrine. 2019; 65(1):81-85. DOI: 10.1007/s12020-019-01912-1. View

16.

Dai L, Deng C, Li Y, Zhu J, Mu Y, Deng Y . Birth weight reference percentiles for Chinese. PLoS One. 2014; 9(8):e104779. PMC: 4134219. DOI: 10.1371/journal.pone.0104779. View

17.

Zhang J, Du M, Li Z, Wang L, Hu J, Zhao B . Fresh versus frozen embryo transfer for full-term singleton birth: a retrospective cohort study. J Ovarian Res. 2018; 11(1):59. PMC: 6048709. DOI: 10.1186/s13048-018-0432-x. View

18.

Fraissinet A, Robin G, Pigny P, Lefebvre T, Catteau-Jonard S, Dewailly D . Use of the serum anti-Müllerian hormone assay as a surrogate for polycystic ovarian morphology: impact on diagnosis and phenotypic classification of polycystic ovary syndrome. Hum Reprod. 2017; 32(8):1716-1722. DOI: 10.1093/humrep/dex239. View

19.

Pigny P, Merlen E, Robert Y, Cortet-Rudelli C, Decanter C, Jonard S . Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab. 2003; 88(12):5957-62. DOI: 10.1210/jc.2003-030727. View

20.

Tata B, Mimouni N, Barbotin A, Malone S, Loyens A, Pigny P . Elevated prenatal anti-Müllerian hormone reprograms the fetus and induces polycystic ovary syndrome in adulthood. Nat Med. 2018; 24(6):834-846. PMC: 6098696. DOI: 10.1038/s41591-018-0035-5. View